Legend Biotech annual shares outstanding
2020
2021
2022
2023
2024
2025
Legend Biotech Shares Outstanding History (LEGN)
Legend Biotech reported 369.9M shares outstanding at the end of fiscal 2025.
View full Legend Biotech company overviewLegend Biotech annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 369.9M | 2.6M | +0.70% |
| 2024 | 2024-12-31 | 367.3M | 3.5M | +0.96% |
| 2023 | 2023-12-31 | 363.8M | 33.7M | +10.20% |
| 2022 | 2022-12-31 | 330.1M | 21.7M | +7.03% |
| 2021 | 2021-12-31 | 308.5M | 42.4M | +15.96% |
| 2020 | 2020-12-31 | 266.0M | — | — |
Legend Biotech quarterly shares outstanding
Q4.19
Q4.20
Q4.21
Q4.22
Q4.23
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 387.5M | 18.4M | +4.98% |
| Q1 2026 | 2026-03-31 | 371.5M | 3.4M | +0.93% |
| Q4 2025 | 2025-12-31 | 369.9M | 2.6M | +0.70% |
| Q3 2025 | 2025-09-30 | 369.4M | — | — |
| Q2 2025 | 2025-06-30 | 369.1M | — | — |
| Q1 2025 | 2025-03-31 | 368.1M | — | — |
| Q4 2024 | 2024-12-31 | 367.3M | 3.5M | +0.96% |
| Q4 2023 | 2023-12-31 | 363.8M | 33.7M | +10.20% |
| Q4 2022 | 2022-12-31 | 330.1M | 21.7M | +7.03% |
| Q4 2021 | 2021-12-31 | 308.5M | 42.4M | +15.96% |
| Q4 2020 | 2020-12-31 | 266.0M | 0 | 0.00% |
| Q4 2019 | 2019-12-31 | 266.0M | — | — |
Legend Biotech shares outstanding trends
Over the last five fiscal years, Legend Biotech's shares outstanding moved from 266.0M to 369.9M, a change of 103.9M. The latest reported quarter, Q2 2026, shows 387.5M.
About the metric
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
Calculation and source
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when a stock-split conversion ratio is reported directly or evidenced by a later filing’s restated historical share balance. After repeated reverse splits, an old period can represent less than one current-basis share; this is a split-adjusted equivalent, not a literal historical certificate count. Values remain as reported when no reliable split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Legend Biotech source filings ↗